Author Interviews, Immunotherapy, Prostate Cancer / 16.07.2016
PD-1 Blocker May Help Some With Metastatic Prostate Cancer
MedicalResearch.com Interview with:
[caption id="attachment_26176" align="alignleft" width="96"]
Dr. Julie Graff[/caption]
Julie Graff, M.D.
Oncologist specializing in prostate cancer
Knight Cancer Institute
Oregon Health & Science University
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Men with metastatic prostate cancer that is not responding to second-line androgen receptor blockade (such as enzalutamide) have a very limited life expectancy. We found that adding immunotherapy to enzalutamide in men whose prostate cancer is no longer responding to enzalutamide could exert a very strong anti-cancer effect. Previous experience with this type of immunotherapy in prostate cancer patients suggested this type immunotherapy does not work in patients with prostate cancer. What we have found will lead to more studies of this agent.
Dr. Julie Graff[/caption]
Julie Graff, M.D.
Oncologist specializing in prostate cancer
Knight Cancer Institute
Oregon Health & Science University
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Men with metastatic prostate cancer that is not responding to second-line androgen receptor blockade (such as enzalutamide) have a very limited life expectancy. We found that adding immunotherapy to enzalutamide in men whose prostate cancer is no longer responding to enzalutamide could exert a very strong anti-cancer effect. Previous experience with this type of immunotherapy in prostate cancer patients suggested this type immunotherapy does not work in patients with prostate cancer. What we have found will lead to more studies of this agent.






















